Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

VOLUNTARY ANNOUNCEMENT APPROVAL RECEIVED FOR MARKETING OT-703 IN HONG KONG

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

INSIDE INFORMATION INCLUSION OF OT-401 IN CHINA NATIONAL REIMBURSEMENT DRUG LIST

INSIDE INFORMATION INCLUSION OF OT-401 IN CHINA NATIONAL REIMBURSEMENT DRUG LIST

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 November 2023

VOLUNTARY ANNOUNCEMENT PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-502 IN CHINA

VOLUNTARY ANNOUNCEMENT PROPOSED ON-MARKET SHARE REPURCHASE

VOLUNTARY ANNOUNCEMENT PATIENT ENROLLMENT COMPLETED IN THE PHASE II CLINICAL TRIAL OF OT-202 IN CHINA

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2023

SUPPLEMENTAL ANNOUNCEMENT

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2023

CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG AND PROCESS AGENT

CHANGE OF JOINT COMPANY SECRETARIES AND AUTHORIZED REPRESENTATIVE

NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS

NOTIFICATION LETTER AND REQUEST FORM TO REGISTERED SHAREHOLDERS

2023 Interim Report

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 August 2023

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023

VOLUNTARY ANNOUNCEMENT PATIENT ENROLLMENT COMPLETED IN THE REAL-WORLD STUDY OF OT-502 IN HAINAN BOAO

NOTICE OF BOARD MEETING

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 July 2023

VOLUNTARY ANNOUNCEMENT CLINICAL TRIAL AUTHORIZATION FOR INITIATING A PHASE III CLINICAL TRIAL OF OT-101-S ACCEPTED IN CHINA

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 June 2023

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 16, 2023

AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 May 2023

VOLUNTARY ANNOUNCEMENT PATIENT ENROLLMENT COMPLETED IN THE GLOBAL MULTI-CENTER PHASE III CLINICAL TRIAL OF OT-101

Next Day Disclosure Return

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 April 2023

VOLUNTARY ANNOUNCEMENT INCLUSION OF OT-1001 IN THE PRIORITY REVIEW AND APPROVAL PROCESS OF THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

2022 Annual Report

2022 Environmental, Social and Governance Report

NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS

FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 16, 2023

NOTIFICATION LETTER AND REQUEST FORM TO REGISTERED SHAREHOLDERS

NOTICE OF ANNUAL GENERAL MEETING

PROPOSED GRANTING OF GENERAL MANDATESTO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF RETIRING DIRECTORS; PROPOSED RE-APPOINTMENT OF AUDITOR; PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION;AND NOTICE OF ANNUAL GENERAL MEETING

VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION FOR OT-1001 ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2023

PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE SIXTH MEMORANDUM AND ARTICLES OF ASSOCIATION

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2022

TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE

DATE OF BOARD MEETING

VOLUNTARY ANNOUNCEMENT PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-702 IN CHINA

VOLUNTARY ANNOUNCEMENT INITIATION OF THE PHASE II CLINICAL TRIAL OF OT-202

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 28 February 2023

POSITIVE PROFIT ALERT

VOLUNTARY ANNOUNCEMENT COMPLETION OF THE PHASE I CLINICAL TRIAL OF OT-202

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 January 2023

VOLUNTARY ANNOUNCEMENT PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-101 IN CHINA

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 December 2022